首页> 美国卫生研究院文献>other >Establishment and Characterization of 7 Novel Hepatocellular Carcinoma Cell Lines from Patient-Derived Tumor Xenografts
【2h】

Establishment and Characterization of 7 Novel Hepatocellular Carcinoma Cell Lines from Patient-Derived Tumor Xenografts

机译:患者源性肿瘤异种移植物中7种新型肝癌细胞系的建立和表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatocellular carcinoma (HCC) is a common cancer with poor prognosis worldwide and the molecular mechanism is not well understood. This study aimed to establish a collection of human HCC cell lines from patient-derived xenograft (PDX) models. From the 20 surgical HCC sample collections, 7 tumors were successfully developed in immunodeficient mice and further established 7 novel HCC cell lines (LIXC002, LIXC003, LIXC004, LIXC006, LIXC011, LIXC012 and CPL0903) by primary culture. The characterization of cell lines was defined by morphology, growth kinetics, cell cycle, chromosome analysis, short tandem repeat (STR) analysis, molecular profile, and tumorigenicity. Additionally, response to clinical chemotherapeutics was validated both in vitro and in vivo. STR analysis indicated that all cell lines were unique cells different from known cell lines and free of contamination by bacteria or mycoplasma. The other findings were quite heterogeneous between individual lines. Chromosome aberration could be found in all cell lines. Alpha-fetoprotein was overexpressed only in 3 out of 7 cell lines. 4 cell lines expressed high level of vimentin. Ki67 was strongly stained in all cell lines. mRNA level of retinoic acid induced protein 3 (RAI3) was decreased in all cell lines. The 7 novel cell lines showed variable sensitivity to 8 tested compounds. LIXC011 and CPL0903 possessed multiple drug resistance property. Sorafenib inhibited xenograft tumor growth of LIXC006, but not of LIXC012. Our results indicated that the 7 novel cell lines with low passage maintaining their clinical and pathological characters could be good tools for further exploring the molecular mechanism of HCC and anti-cancer drug screening.
机译:肝细胞癌(HCC)是全球范围内预后较差的常见癌症,其分子机制尚不清楚。这项研究旨在从患者源异种移植(PDX)模型中建立人类HCC细胞系的集合。从20个外科手术HCC样本收集物中,在免疫缺陷小鼠中成功开发了7种肿瘤,并通过原代培养进一步建立了7种新型HCC细胞系(LIXC002,LIXC003,LIXC004,LIXC006,LIXC011,LIXC012和CPL0903)。通过形态学,生长动力学,细胞周期,染色体分析,短串联重复序列(STR)分析,分子谱和致瘤性来定义细胞系的特征。另外,在体外和体内均证实了对临床化学疗法的反应。 STR分析表明,所有细胞系都是不同于已知细胞系的独特细胞,并且不受细菌或支原体的污染。其他发现在各个品系之间非常不同。在所有细胞系中均可发现染色体畸变。甲胎蛋白仅在7个细胞系中的3个中过表达。 4个细胞系表达高水平的波形蛋白。 Ki67在所有细胞系中均被强烈染色。维甲酸诱导的蛋白3(RAI3)的mRNA水平在所有细胞系中均降低。 7种新型细胞系对8种测试化合物表现出不同的敏感性。 LIXC011和CPL0903具有多重耐药性。索拉非尼抑制LIXC006的异种移植瘤生长,但不抑制LIXC012。我们的结果表明,这7种低传代的新型细胞系保持了其临床和病理学特征可能是进一步探索HCC分子机制和抗癌药物筛选的良好工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号